Can You Regain Weight After Stopping Retatrutide? What the Evidence Shows

Introduction

The short answer is yes. Weight regain after stopping retatrutide is expected — not because the drug fails, but because of how obesity works as a chronic disease.

Retatrutide suppresses appetite and increases energy expenditure while you're taking it. When you stop, those effects reverse. Appetite-regulating hormones return toward pre-treatment levels, metabolic rate begins to decline, and the body gradually recovers the weight it had defended before treatment. This isn't a failure of willpower — it's biology.

The more relevant questions are: how quickly does regain begin, how much comes back, and how does retatrutide's unusually high starting efficacy affect the arithmetic of stopping? Here's what the current evidence shows.

What Retatrutide's Own Data Says

Published retatrutide data on stopping is limited to a 4-week off-treatment follow-up period at the end of the Phase 2 obesity trial (Jastreboff et al., NEJM 2023). This was not a designed withdrawal study — it was a brief safety observation window. What it showed:

Weight regain began within 2–3 weeks of the final dose. Appetite returned. The degree of regain over just 4 weeks was modest given the short window, but the direction was clear and consistent across participants.

The Phase 2a MASLD substudy (Sanyal et al., Nature Medicine 2024) confirmed the same pattern: "Some weight regain was observed at the safety follow-up visit 4 weeks after discontinuation of treatment."

These are brief observations from the end of a 48-week Phase 2 program — not a controlled withdrawal trial. What they confirm is the onset of regain, not its trajectory or final magnitude. For that, we rely on the closest available proxies: semaglutide and tirzepatide withdrawal data.

No Phase 3 retatrutide discontinuation trial has been published. TRIUMPH-6 (NCT06859268) is a weight maintenance trial, but it is not specifically designed as a withdrawal study.

Why Weight Returns: The Biology of Stopping

All GLP-1 receptor agonists — including retatrutide — work by suppressing appetite and altering metabolic signaling while the drug is active. When treatment ends, two things happen simultaneously.

First, the pharmacological suppression clears within 4–5 weeks (retatrutide has a half-life of approximately 6–7 days, so drug levels drop substantially within 3–4 weeks of the last dose). As levels fall, appetite-regulating hormones — particularly ghrelin — begin returning toward their pre-treatment baseline. Hunger increases.

Second, in retatrutide's case specifically, the glucagon receptor component contributes to the drug's higher metabolic rate effect. When glucagon activation stops, resting energy expenditure may decrease more sharply than it does with pure GLP-1 agonists. This is a theoretical concern rather than a confirmed observation — no direct data exists on retatrutide's off-treatment metabolic rate trajectory — but it's worth noting given the mechanistic difference.

The biological reality: obesity is a chronic disease with a physiologically defended set point. Pharmacotherapy manages it while the drug is present. Stopping treatment removes the management while the underlying condition remains.

What the Proxy Evidence Shows: Semaglutide and Tirzepatide Withdrawal

Since no published retatrutide withdrawal trial exists, the best available evidence comes from the STEP 4 (semaglutide) and SURMOUNT-4 (tirzepatide) withdrawal trials.

STEP 1 Trial Extension (Wilding et al., Diabetes, Obesity and Metabolism, 2022) — Semaglutide withdrawal:

Participants in the STEP 1 trial lost an average of 17.3% of body weight over 68 weeks on semaglutide 2.4mg. At week 68, treatment was stopped and participants entered a 52-week off-treatment extension.

Those who stopped semaglutide regained weight progressively throughout the follow-up. By week 120 — one year after stopping — participants maintained only 5.6% net weight loss from their original baseline, meaning they had regained approximately two-thirds of what they had lost. Cardiometabolic improvements largely reversed alongside the weight regain.

SURMOUNT-4 (Aronne et al., JAMA, 2023) — Tirzepatide withdrawal:

After a 36-week lead-in achieving a mean 20.9% weight loss on tirzepatide, participants were randomized to continue tirzepatide or switch to placebo for 52 weeks. Those who discontinued regained 14.0% of body weight relative to their post-lead-in weight over the following year — ending with approximately 9.9% net weight loss from their original baseline. Those who continued tirzepatide lost an additional 5.5%.

The pattern across both trials is consistent: weight regain begins early, progresses over months, and typically returns approximately two-thirds of the original loss within a year of stopping. Metabolic improvements — blood pressure, glucose, lipids — largely reverse alongside the weight regain.

The Retatrutide-Specific Arithmetic

Here is the insight that makes retatrutide's situation genuinely different from semaglutide or tirzepatide: because retatrutide produces a substantially larger initial weight loss, the same proportional regain translates to a different absolute picture.

Using the two-thirds regain estimate from STEP 4 and SURMOUNT-4 as a proxy — and applying it to a 250 lb (113 kg) baseline patient:

These are projections based on STEP 4 and SURMOUNT-4 regain patterns applied to retatrutide's Phase 3 weight loss results. No retatrutide-specific withdrawal trial data exists. Individual results will vary.

The paradox of higher efficacy: a retatrutide patient who stops treatment will regain more pounds in absolute terms than a semaglutide patient — but they will also maintain more weight loss in absolute terms. Higher starting efficacy means both larger absolute regain and larger absolute maintained loss.

A separate, important caveat: it is unknown whether retatrutide's glucagon receptor component produces faster or more complete regain than pure GLP-1 agonists. The glucagon-driven metabolic rate increase may unwind more sharply when treatment stops, potentially making retatrutide regain faster than STEP 4 and SURMOUNT-4 suggest. This is a hypothesis, not a confirmed finding.

What TRIUMPH-6 Will Tell Us

TRIUMPH-6 (NCT06859268) is retatrutide's weight maintenance trial — the closest thing to a long-term withdrawal and maintenance study in the TRIUMPH program. Its design includes a weight-loss lead-in phase on retatrutide followed by a randomized phase where participants either continue treatment, switch to a lower maintenance dose, or switch to placebo.

TRIUMPH-6 results will provide the first systematic retatrutide-specific data on what happens to weight when the drug is stopped or dose-reduced after significant loss. Results are expected no earlier than 2027.

Until then, STEP 4 and SURMOUNT-4 remain the best available guides.

Practical Implications

For patients and clinicians considering retatrutide when it becomes available in 2028, the withdrawal evidence from the GLP-1 class carries a direct implication: this is a chronic medication for a chronic disease.

The evidence from semaglutide and tirzepatide is consistent — stopping treatment leads to substantial regain for most patients within a year. The metabolic improvements that accompany weight loss reverse alongside it. Treating retatrutide as a short-term intervention and planning to stop after reaching a target weight is likely to produce disappointment.

Strategies with the best evidence base for minimizing regain after stopping any GLP-1 medication:

Resistance training and physical activity during treatment help build or preserve muscle mass that contributes to a higher resting metabolic rate after stopping. This attenuates but does not eliminate the regain trajectory.

Dietary habits established during treatment matter more after stopping than during. Patients who develop sustainable eating patterns while on treatment maintain better outcomes than those who relied entirely on pharmacological appetite suppression.

Gradual tapering rather than abrupt stopping may slow the rate of appetite return. No controlled trial has tested tapering specifically with retatrutide, but the theoretical basis is sound — slower drug clearance gives more time for behavioral adaptation.

For a comprehensive overview of what long-term retatrutide treatment looks like and what TRIUMPH-6 will measure, see our long-term safety guide.

Conclusion

Weight regain after stopping retatrutide is not a question of if — it's a question of how much and how fast. Phase 2 data confirms that regain begins within 2–3 weeks of the final dose. Semaglutide and tirzepatide withdrawal trials show that approximately two-thirds of lost weight returns within a year of stopping for most patients.

Retatrutide's higher starting efficacy means the absolute amount regained will be larger than with current medications — but so will the amount maintained. The net outcome after stopping retatrutide is expected to leave patients substantially better off than if they had never treated at all.

The honest conclusion: retatrutide is likely to be a lifelong medication for most patients who use it. For those who cannot continue long-term, the focus should be on building the lifestyle infrastructure during treatment that gives the best chance of maintaining results after stopping.

TRIUMPH-6 will provide retatrutide-specific withdrawal data. Until then, STEP 4 and SURMOUNT-4 are the most reliable guides available.

Sources

• Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism, 2022;24(8):1554–1564.
• Aronne LJ, et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA, 2023;330(22):2161–2172.
• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine, 2023;389:514–526.
• Sanyal AJ, et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease." Nature Medicine, 2024;30:2037–2048.
• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.
• ClinicalTrials.gov: TRIUMPH-6 weight maintenance trial (NCT06859268).